Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model
- 1 May 1996
- journal article
- Published by Elsevier BV in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 58 (2), 139-146
- https://doi.org/10.1016/0960-0760(96)00018-0
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Intermittent androgen suppression in the treatment of prostate cancer: A preliminary reportUrology, 1995
- Derivation of androgen‐independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cellsInternational Journal of Cancer, 1994
- Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III eortc trial (30853)Urology, 1993
- Prostate and Bone Fibroblasts Induce Human Prostate Cancer Growth in Vivo: Implications for Bidirectional Tumor-Stromal Cell Interaction in Prostate Carcinoma Growth and MetastasisJournal of Urology, 1992
- Combination of anandron with orchiectomy in treatment of metastatic prostate cancer: Results of a double-blind studyUrology, 1991
- Clonal adaptation during carcinogenesisBiochemical Pharmacology, 1990
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989
- Molecular cloning of human prostate specific antigen cDNAFEBS Letters, 1987
- The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancerThe Prostate, 1984